Background: Transjugular intrahepatic shunt (TIPSS) is placed in patients with variceal bleeding, refractory ascites, and for other indications. Postprocedural liver function-associated complications (LFAC), including hepatic encephalopathy (HE) and liver failure, represent a major setback. Current methods to predict complications are insufficient. Objectives: We investigated in a pilot study of patients prior TIPSS placement whether the risk of LFAC correlates with the functional reserve of the liver, as assessed by liver maximum function capacity (LiMAx) test. Methods: Prospectively we included patients prior TIPSS placement between June 2016 and November 2017 at Saarland University Medical Center. LiMAx was conducted before and after TIPSS placement. Patients with HE prior TIPSS, as well as other factors predisposing to HE, including concomitant sedative drugs, current bacterial infections and sepsis, were excluded. Overt HE (OHE), LiMAx, and laboratory values were assessed before and after TIPSS placement. Data were analyzed in multivariate regression and AUROC models. Results: Mean age was 60 ± 8 years. Patients (n = 20) were mainly men (65%), and presented predominantly with Child-Pugh class B (90%). Indications for TIPSS were most commonly refractory ascites or recurrent variceal bleeding. In total, 40% of the patients developed LFAC after TIPSS placement. Expectedly, LiMAx decreased and serum bilirubin increased after TIPSS. LiMAx drop ≥20% was the only parameter predicting the development of LFAC after TIPSS in multivariate regression and AUROC analysis. Conclusions: In multivariate regression models and AUROC analysis, a drop in LiMAx predicted the development of LFAC after TIPSS placement. Additional larger studies assessing OHE and early liver failure separately are warranted.

Keywords:
Hepatic encephalopathy, Liver function, Liver cirrhosis, Liver failure, Maximum liver function capacity, Transjugular intrahepatic portosystemic shunt
1.
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
J Hepatol
. 2010 Sep;53(3):397–417.
2.
Rössle M. TIPS: 25 years later.
J Hepatol
. 2013 Nov;59(5):1081–93.
3.
García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al.; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding.
N Engl J Med
. 2010 Jun;362(25):2370–9.
4.
de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
J Hepatol
. 2015 Sep;63(3):743–52.
5.
Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
Clin Liver Dis
. 2012 Feb;16(1):133–46.
6.
Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts.
Am J Gastroenterol
. 2008 Nov;103(11):2738–46.
7.
Casadaban LC, Parvinian A, Minocha J, Lakhoo J, Grant CW, Ray CE Jr, et al. Clearing the confusion over hepatic encephalopathy after tips creation: Incidence, prognostic factors, and clinical outcomes.
Dig Dis Sci
. 2015 Apr;60(4):1059–66.
8.
Fidelman N, Kwan SW, LaBerge JM, Gordon RL, Ring EJ, Kerlan RK Jr. The transjugular intrahepatic portosystemic shunt: an update.
AJR Am J Roentgenol
. 2012 Oct;199(4):746–55.
9.
Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review.
J Gastroenterol Hepatol
. 2011 Jun;26(6):943–51.
10.
Zuckerman DA, Darcy MD, Bocchini TP, Hildebolt CF. Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors.
AJR Am J Roentgenol
. 1997 Dec;169(6):1727–31.
11.
Bettinger D, Schultheiss M, Boettler T, Muljono M, Thimme R, Rössle M. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS).
Aliment Pharmacol Ther
. 2016 Nov;44(10):1051–61.
12.
Gaba RC, Couture PM, Bui JT, Knuttinen MG, Walzer NM, Kallwitz ER, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.
J Vasc Interv Radiol
. 2013 Mar;24(3):411–20, 420.e1–4; quiz 421.
13.
Routhu M, Safka V, Routhu SK, Fejfar T, Jirkovsky V, Krajina A, et al. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS).
Ann Hepatol
. 2017 Jan-Feb;16(1):140–8.
14.
Forestier J, Dumortier J, Guillaud O, Ecochard M, Roman S, Boillot O, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests.
Eur J Gastroenterol Hepatol
. 2010 May;22(5):532–40.
15.
Oellerich M, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.
Ther Drug Monit
. 1990 May;12(3):219–26.
16.
Mion F, Queneau PE, Rousseau M, Brazier JL, Paliard P, Minaire Y. Aminopyrine breath test: development of a 13C-breath test for quantitative assessment of liver function in humans.
Hepatogastroenterology
. 1995 Nov-Dec;42(6):931–8.
17.
Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C.
Liver
. 2001 Aug;21(4):260–5.
18.
Park GJ, Katelaris PH, Jones DB, Seow F, Le Couteur DG, Ngu MC. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function.
Hepatology
. 2003 Nov;38(5):1227–36.
19.
Baron A, Gulberg V, Sauter G, Waggershauser T, Reiser M, Gerbes AL. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
Hepatogastroenterology
. 1998 Nov-Dec;45(24):2315–21.
20.
Malinowski M, Jara M, Lüttgert K, Orr J, Lock JF, Schott E, et al. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test.
Dig Dis Sci
. 2014 Dec;59(12):2983–91.
21.
Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity.
Ann Surg
. 2009 Jul;250(1):119–25.
22.
Lock JF, Malinowski M, Seehofer D, Hoppe S, Röhl RI, Niehues SM, et al. Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity.
Langenbecks Arch Surg
. 2012 Dec;397(8):1297–304.
23.
Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery.
HPB (Oxford)
. 2010 Mar;12(2):139–46.
24.
Ochs A, Rössle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.
N Engl J Med
. 1995 May;332(18):1192–7.
25.
Rössle M, Grandt D. TIPS: an update.
Best Pract Res Clin Gastroenterol
. 2004 Feb;18(1):99–123.
26.
Pfaffenbach B, Gotze O, Szymanski C, Hagemann D, Adamek RJ. [The 13C-methacetin breath test for quantitative noninvasive liver function analysis with an isotope-specific nondispersive infrared spectrometer in liver cirrhosis].
Dtsch Med Wochenschr
. 1998 Dec 4;123(49):1467–71.
27.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the european association for the study of the liver.
Hepatology
. 2014 Aug;60(2):715–35.
28.
Luca A, Miraglia R, Maruzzelli L, D’Amico M, Tuzzolino F. Early liver failure after transjugular intrahepatic portosystemic shunt in patients with cirrhosis with model for end-stage liver disease score of 12 or less: Incidence, outcome, and prognostic factors.
Radiology
. 2016 Aug;280(2):622–9.
29.
Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis.
J Vasc Interv Radiol
. 2002 Feb;13(2 Pt 1):155–61.
30.
Ripamonti R, Ferral H, Alonzo M, Patel NH. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.
Semin Intervent Radiol
. 2006 Jun;23(2):165–76.
31.
Patch D, Nikolopoulou V, McCormick A, Dick R, Armonis A, Wannamethee G, et al. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding.
J Hepatol
. 1998 Mar;28(3):454–60.
32.
Bañares R, Casado M, Rodríguez-Láiz JM, Camúñez F, Matilla A, Echenagusía A, et al. Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding.
Am J Gastroenterol
. 1998 Jan;93(1):75–9.
33.
Rubin RA, Haskal ZJ, O’Brien CB, Cope C, Brass CA. Transjugular intrahepatic portosystemic shunting: decreased survival for patients with high APACHE II scores.
Am J Gastroenterol
. 1995 Apr;90(4):556–63.
34.
Yao J, Zuo L, An G, Yue Z, Zhao H, Wang L, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal hypertension.
J Gastrointestin Liver Dis
. 2015 Sep;24(3):301–7.
35.
Mamiya Y, Kanazawa H, Kimura Y, Narahara Y, Yamate Y, Nakatsuka K, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
Hepatol Res
. 2004 Nov;30(3):162–8.
36.
Sauer P, Hansmann J, Richter GM, Stremmel W, Stiehl A. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial.
Endoscopy
. 2002 Sep;34(9):690–7.
37.
Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage.
J Hepatol
. 1995 Aug;23(2):123–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.